Nicox S.A. Logo

Nicox S.A.

COX | PA

Overview

Corporate Details

ISIN(s):
FR0013018124 (+6 more)
LEI:
969500EZGEO9W4JXR353
Country:
France
Address:
SOPHIA, 06410 BIOT
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutics to maintain vision and improve ocular health. The company's primary business involves creating and advancing a pipeline of investigational drugs for ophthalmological diseases. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop in development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. Nicox advances its portfolio through in-house research and strategic partnerships with other pharmaceutical companies for clinical development and commercialization.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Nicox S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-26 07:30
Regulatory News Service
Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site i…
French 155.8 KB
2025-08-26 07:30
Regulatory News Service
Nicox Announces Shareholder Q&A Webpage Available
English 153.6 KB
2025-08-12 15:53
Declaration of Voting Results & Voting Rights Announcements
Franchissement de seuils
French 113.6 KB
2025-08-08 07:30
Share Issue/Capital Change
Nicox Extends Existing Flexible Equity Financing
English 181.9 KB
2025-08-05 07:30
Regulatory News Service
Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase…
French 176.0 KB
2025-08-05 07:30
Regulatory News Service
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
English 171.5 KB
2025-06-30 07:30
Earnings Release
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Dena…
French 161.2 KB
2025-06-30 07:30
Regulatory News Service
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
English 156.1 KB
2025-06-06 07:30
Pre-Annual General Meeting Information
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 ju…
French 184.6 KB
2025-06-06 07:30
Pre-Annual General Meeting Information
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 2…
English 175.2 KB
2025-05-27 07:30
Earnings Release
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX…
English 179.6 KB
2025-05-27 07:30
Earnings Release
Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Ko…
French 183.6 KB
2025-05-14 07:30
Earnings Release
Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans l…
French 199.5 KB
2025-05-14 07:30
Regulatory News Service
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
English 184.4 KB
2025-04-30 07:30
Earnings Release
Nicox Provides Full Year 2024 Financial Results
English 181.9 KB

Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Nicox S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN